Bacterial Vaginosis Emerging Research and Trials to Watch

What Is Bacterial Vaginosis and Why Does It Keep Coming Back?

Bacterial vaginosis is not a simple infection. It is a polymicrobial disruption of the vaginal microbiome in which the normally dominant Lactobacillus species are displaced by a dense, adherent biofilm anchored by Gardnerella vaginalis and supported by anaerobes including Prevotella, Mobiluncus, Fusobacterium, and BVAB1/BVAB2. Diagnosis requires meeting at least 3 of the 4 Amsel criteria: homogeneous gray-white discharge, vaginal pH above 4.5, a positive whiff test with 10% KOH, and clue cells on wet mount. The Nugent scoring system applied to Gram stain remains the research gold standard.

Recurrence is the defining clinical problem. After a standard 7-day course of oral metronidazole, up to 58% of women experience a recurrence within 12 months. The reason is structural: antibiotics suppress the bacterial load but do not eradicate the G. Vaginalis biofilm or restore a Lactobacillus-dominant community. Once antibiotics clear, the biofilm reseeds the vaginal epithelium and the cycle restarts.

Why Your Hormonal Status Changes Your BV Risk

Estrogen is the primary driver of vaginal Lactobacillus colonization. Estrogen stimulates glycogen deposition in vaginal epithelial cells; Lactobacillus ferments that glycogen into lactic acid, keeping vaginal pH below 4.5 and creating an environment hostile to anaerobes.

When estrogen falls, including during late perimenopause, postmenopause without hormone therapy, the postpartum period, and hypothalamic amenorrhea from low body weight or over-exercise, this protective mechanism weakens. Postmenopausal women not using vaginal estrogen show lower rates of Lactobacillus dominance and higher vaginal pH, which does not always produce symptomatic BV but does raise susceptibility.

For women with PCOS, the picture is complicated. Androgen excess and insulin resistance alter the vaginal environment independently of estrogen levels, and PCOS is associated with a higher prevalence of bacterial vaginosis compared with cycle-matched controls, though the mechanism is not yet fully characterized.

The Biofilm Problem That Most Treatments Ignore

The G. Vaginalis biofilm is the single biggest barrier to cure. In vitro studies show that G. Vaginalis produces a biofilm within 24 hours of inoculation, and that biofilm confers substantial antibiotic tolerance. Metronidazole and clindamycin disrupt planktonic bacteria efficiently, but the sessile bacteria within the biofilm require concentrations that standard dosing does not achieve in vaginal tissue. This is why the 7-day oral course outperforms the 5-day vaginal gel regimen in women with recurrent BV: longer exposure partially penetrates the biofilm. It is also why several new agents specifically target biofilm dispersal.

Current Standard-of-Care Treatments

The CDC 2021 STI Treatment Guidelines list three first-line options for non-pregnant adults:

• Metronidazole 500 mg oral twice daily for 7 days
• Metronidazole 0.75% gel 5 g intravaginally once daily for 5 days
• Clindamycin 2% cream 5 g intravaginally at bedtime for 7 days

Tinidazole 2 g oral once daily for 2 days and secnidazole 2 g oral single-dose granules are approved alternatives. Secnidazole's single-dose convenience improves adherence, which matters because incomplete courses are strongly associated with recurrence.

Suppressive Therapy for Recurrent BV

For women with three or more confirmed episodes per year, the CDC recommends metronidazole 0.75% gel twice weekly for 16 weeks as suppressive maintenance after an initial treatment course. This reduces recurrence during the suppressive period, but recurrence rates after stopping suppression remain high, approaching pre-treatment levels within 3 to 6 months.

Boric acid 600 mg intravaginal suppositories are used off-label as adjunctive therapy for recurrent BV, with one RCT showing a statistically significant reduction in recurrence when boric acid was added to metronidazole treatment. Boric acid is an abortifacient and is absolutely contraindicated in pregnancy.

What Does Not Work (Despite Popular Belief)

Oral probiotics containing Lactobacillus rhamnosus GR-1 and L. Reuteri RC-14 have a plausible mechanism and one systematic review found modest benefit in reducing BV recurrence rates, but effect sizes are small and evidence consistency is low. Over-the-counter vaginal acidifiers alone have not shown efficacy in adequately powered trials. Treating male partners with oral metronidazole did not reduce BV recurrence in women in the landmark 2021 DESTINY trial, which enrolled 789 couples. Male partner treatment is not recommended.

Emerging Therapies: The Trials That Could Change Everything

This is where the real momentum sits. Several agents are in Phase 2 or Phase 3 testing, and two have already produced data strong enough to shift clinical thinking.

LACTIN-V: A Live Biotherapeutic Product

LACTIN-V is a vaginal capsule containing Lactobacillus crispatus CTV-05, a strain selected because L. Crispatus is the species most strongly associated with vaginal health and lowest BV risk. The strategy is to recolonize the vagina with a beneficial organism after antibiotics clear the pathogenic load.

The Phase 2b randomized trial published in the New England Journal of Medicine in 2020 enrolled 228 women aged 18 to 45 with symptomatic BV. After metronidazole gel induction, women receiving LACTIN-V had a BV recurrence rate of 30% at 24 weeks compared with 45% in the placebo group, an absolute risk reduction of 15 percentage points. The number needed to treat was approximately 7. No serious adverse events were attributed to LACTIN-V. A Phase 3 trial (NCT04799821) is ongoing, with results expected in 2025-2026.

Ovaprene and the Hormonal Contraception Intersection

An intriguing secondary finding from BV microbiome research is that non-daily vaginal contraceptive rings alter vaginal ecology. The Ovaprene ring, designed as a hormone-free contraceptive, has been observed in Phase 2/3 studies to maintain or improve vaginal Lactobacillus dominance in a subset of users, raising the question of whether a contraceptive device could simultaneously reduce BV risk in women using it for pregnancy prevention. This matters for women who are not trying to conceive and who also struggle with recurrent BV.

TOL-463: A Novel Intravaginal Boric Acid Formulation

TOL-463 is an enhanced-delivery intravaginal boric acid formulation designed to penetrate the G. Vaginalis biofilm more effectively than standard compounded boric acid suppositories. A Phase 2 trial of TOL-463 reported a 65% clinical cure rate at test-of-cure for BV, with a favorable safety profile. Phase 3 data have not yet been published as of early 2025.

Phage Therapy: Early-Stage but Conceptually Significant

Bacteriophages are viruses that selectively lyse specific bacterial species. Researchers at several academic centers are investigating phages that specifically target G. Vaginalis while leaving Lactobacillus strains intact. This approach would address the biofilm problem without the collateral microbiome disruption caused by broad-spectrum antibiotics. Human trials have not yet started, but preclinical in vitro and mouse model data published in 2023 showed near-complete G. Vaginalis biofilm eradication with a G. Vaginalis-specific phage. The specificity is the key advantage.

Vaginal Microbiome Transplant: Proof of Concept

Taking direct inspiration from fecal microbiome transplant for C. Difficile, a South African research group conducted the first-in-human vaginal microbiome transplant (VMT) in 5 women with recurrent BV, transferring vaginal secretions from L. Crispatus-dominant donors. All 5 recipients achieved a Lactobacillus-dominant vaginal microbiome at 4 weeks, with 4 of 5 remaining recurrence-free at 16 weeks. This is very early-stage, proof-of-concept work. Donor screening, standardization, and safety data for larger populations do not yet exist. A Phase 1 safety trial is being designed.

The WomanRx Recurrence-Risk Framework: Not all BV is the same, and emerging research is starting to define biologically distinct subtypes that may predict treatment response. Women with a BVAB1-dominant community appear to have higher recurrence rates than those with a G. Vaginalis-dominant community. Women with L. Crispatus as even a minor community member at baseline respond better to LACTIN-V recolonization than women with no detectable L. Crispatus. Clinicians and researchers are now discussing whether a one-time vaginal microbiome profile at diagnosis could stratify women into treatment pathways: standard antibiotics for first-episode low-BVAB1 disease, antibiotics plus LACTIN-V for L. Crispatus-present women with prior recurrence, and investigational biofilm-disrupting agents for G. Vaginalis-biofilm-dominant, L. Crispatus-absent women. This framework does not yet exist in any published guideline, but the LACTIN-V Phase 3 trial is collecting microbiome-stratified outcome data that should clarify it.

Advances in Diagnosis

Molecular Testing Is Changing the Accuracy Floor

Traditional Amsel criteria have a sensitivity of approximately 70 to 80% compared with Nugent scoring as the reference standard. Clinician-dependent variations in performing and interpreting the whiff test and wet mount introduce meaningful error. FDA-cleared nucleic acid amplification tests (NAATs) for BV now available include the Aptima BV assay (Hologic) and BD MAX vaginal panel, both of which detect G. Vaginalis, A. Vaginae, and BVAB2 with sensitivities exceeding 90% in clinical validation studies.

The clinical question is whether molecular testing changes outcomes. A woman diagnosed by NAAT rather than Amsel criteria is more likely to have her BV correctly identified, but the treatment is the same. The bigger opportunity is in using quantitative microbial data to guide maintenance therapy decisions and to identify the women most likely to benefit from emerging biotherapeutics.

Self-Sampling and At-Home Diagnostics

Several companies now offer clinician-ordered at-home vaginal swab kits that test for BV using PCR-based panels. One study validated at-home self-collected vaginal swabs against clinician-collected swabs and found greater than 95% agreement for G. Vaginalis detection. Self-sampling removes access barriers for women who cannot easily attend a clinic, and the data suggest it is diagnostically equivalent for most BV-associated organisms. The WomanRx clinical team uses self-collected swabs routinely for telehealth-based BV assessment and monitoring.

BV Across Life Stages

Reproductive Years: Recurrence as the Central Problem

Women aged 15 to 44 carry the highest burden of BV. Sexual activity, new or multiple partners, receptive oral sex, and lack of condom use are all associated with higher BV rates, though BV is not classified as a sexually transmitted infection. Black women in the U.S. Have a BV prevalence of approximately 51% compared with 23% in white women, a disparity that is not explained by sexual behavior differences and likely reflects a combination of socioeconomic stressors, differences in baseline vaginal microbiome ecology, and reduced access to timely treatment. This disparity is a direct target of the LACTIN-V Phase 3 trial's recruitment strategy, which is enrolling at least 50% Black participants.

Trying to Conceive and Fertility

BV is associated with reduced IVF success rates. A 2018 meta-analysis of 12 studies found that BV at the time of embryo transfer was associated with a significantly lower clinical pregnancy rate, with an odds ratio of approximately 0.6. ACOG and ASRM both support screening and treating BV before assisted reproductive procedures. Women undergoing IUI or IVF who have recurrent BV should discuss a course of metronidazole or clindamycin timed to their transfer cycle with their reproductive endocrinologist.

Pregnancy: A High-Stakes Context

BV in pregnancy is associated with preterm birth, preterm premature rupture of membranes, and postpartum endometritis. The USPSTF does not recommend routine BV screening in asymptomatic low-risk pregnant women, citing insufficient evidence that treatment in asymptomatic women reduces preterm birth. However, symptomatic BV in pregnancy is treated.

Safe treatment options in pregnancy:

• Metronidazole 500 mg oral twice daily for 7 days (preferred)
• Metronidazole 250 mg oral three times daily for 7 days (alternative)
• Clindamycin 300 mg oral twice daily for 7 days

Metronidazole has been used extensively in pregnancy. A 2011 Cochrane review of metronidazole use in the first trimester found no significant increase in birth defects, though many clinicians still prefer to avoid it in the first 12 weeks when organogenesis is most active. Intravaginal clindamycin cream is not recommended in pregnancy because an increased rate of neonatal adverse events was observed in some studies with intravaginal clindamycin. Boric acid is absolutely contraindicated in pregnancy due to fetal toxicity and teratogenicity.

Tinidazole and secnidazole should be avoided in pregnancy; human safety data are insufficient and animal data raise concern.

Postpartum and Lactation

Metronidazole passes into breast milk. The American Academy of Pediatrics classifies metronidazole as compatible with breastfeeding when used in the standard 7-day oral course. Some clinicians recommend discarding breast milk for 12 to 24 hours after a large single-dose metronidazole regimen (2 g), but this is not necessary with the divided-dose 7-day regimen. Clindamycin is also detectable in breast milk; monitor the infant for diarrhea and rash.

LACTIN-V has not been studied in pregnancy or lactation. Intravaginal boric acid should not be used postpartum until vaginal healing is confirmed.

Perimenopause and Postmenopause

Perimenopause brings erratic estrogen fluctuations and eventually sustained estrogen deficiency, both of which reduce Lactobacillus colonization. Many midlife women are surprised to receive a BV diagnosis after years without vaginal symptoms; the mechanism is hormonal rather than behavioral. Vaginal estrogen therapy restores glycogen-rich epithelium and has been shown to increase Lactobacillus relative abundance in postmenopausal women, making it a rational adjunct to antibiotic treatment in women who have no contraindication to local estrogen.

For women with genitourinary syndrome of menopause (GSM) who also experience recurrent BV, addressing the estrogen deficiency component of their vaginal ecology may reduce the antibiotic treatment burden. This is an area where the evidence is observational and an RCT would be informative, but none has been completed to date.

Who This May Be Right For and Who Should Be Cautious

Women Most Likely to Benefit from Emerging Therapies

• Women with three or more confirmed BV episodes per year who have completed at least one course of suppressive metronidazole gel
• Women with detectable L. Crispatus on vaginal microbiome testing (better predicted response to LACTIN-V based on Phase 2b sub-analysis data)
• Women undergoing fertility treatment where BV recurrence is disrupting cycle timing
• Perimenopausal women in whom concurrent vaginal estrogen therapy has not been offered

Women Who Need Additional Caution

• Pregnant women: standard antibiotics are safe and indicated for symptomatic BV; no emerging therapy has adequate pregnancy safety data yet
• Women with a latex or silicone allergy: clindamycin cream contains mineral oil and may weaken latex condoms and diaphragms for up to 72 hours after use
• Women with a history of C. Difficile colitis: oral clindamycin carries a higher C. Difficile risk than metronidazole and should be avoided if there is a prior history
• Women on warfarin: metronidazole inhibits CYP2C9 and significantly potentiates warfarin; INR monitoring is needed

The Evidence Gap: What We Still Do Not Know

Women have been underrepresented in BV pathophysiology research relative to the scale of the problem. Several gaps are worth naming explicitly.

The racial disparity in BV prevalence has been documented for decades, yet most published treatment-efficacy trials enrolled predominantly white participants, meaning cure rates and recurrence rates in Black women from these trials are either extrapolated or based on small sub-groups. The LACTIN-V Phase 3 trial's diversity recruitment target is a direct response to this criticism and represents a meaningful methodological improvement.

Data on BV treatment efficacy in transgender men and gender-diverse individuals with a uterus and vagina are almost entirely absent from the literature. Clinical practice in this population follows BV guidelines designed for cisgender women, with no direct evidence base.

Long-term safety data for LACTIN-V beyond 24 weeks, and for VMT beyond 16 weeks, do not exist. Regulatory approval of any live biotherapeutic for BV will require extended follow-up data that are still being collected.

Practical Steps You Can Take Now

While LACTIN-V and phage therapy await Phase 3 results, several evidence-based steps reduce recurrence risk today:

1. Complete the full antibiotic course. Stopping at symptom resolution, which often happens by day 3, is a common driver of incomplete biofilm suppression.
2. Avoid vaginal douching. Douching is associated with a 2-fold increase in BV risk and disrupts the vaginal microbiome acutely.
3. Use condoms consistently. Male and female condoms reduce BV recurrence in heterosexually active women, likely by reducing semen-induced vaginal pH changes.
4. Ask about vaginal estrogen if you are perimenopausal or postmenopausal and experiencing recurrent BV. This is an underused adjunct with a strong biological rationale.
5. Ask your clinician about suppressive therapy (metronidazole 0.75% gel twice weekly for 16 weeks) if you have had three or more episodes in 12 months. This is guideline-supported and significantly reduces within-treatment-period recurrence.
6. Discuss enrollment in a clinical trial. ClinicalTrials.gov lists ongoing BV trials, including the LACTIN-V Phase 3 study, with sites across the United States.

If your BV is confirmed by molecular testing rather than Amsel criteria alone, ask for the full panel result. Knowing whether your community contains L. Crispatus at baseline may become clinically actionable within the next two to three years as biotherapeutic options reach approval.